Saitama Medical University International Medical Center
Welcome,         Profile    Billing    Logout  
 4 Trials 
31 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fujiwara, Keiichi
ATHENA, NCT03522246 / 2017-004557-17: A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy

Checkmark From monotherapy portion of P3 ATHENA trial for 1L ovarian cancer maintenance setting at IGCS 2022
Sep 2022 - Sep 2022: From monotherapy portion of P3 ATHENA trial for 1L ovarian cancer maintenance setting at IGCS 2022
Checkmark PFS data for 1L ovarian cancer based on ATHENA-MONO trial
Sep 2022 - Sep 2022: PFS data for 1L ovarian cancer based on ATHENA-MONO trial
Checkmark From ATHENA trial in combination with Opdivo for 1L ovarian cancer
More
Active, not recruiting
3
1097
Europe, Canada, Japan, US, RoW
Rucaparib, Rubraca, CO-338, Nivolumab, Opdivo, BMS-936558, Placebo Oral Tablet, Placebo IV Infusion
pharmaand GmbH, Bristol-Myers Squibb, Gynecologic Oncology Group, European Network of Gynaecological Oncological Trial Groups (ENGOT), Foundation Medicine
Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed, FIGO Stage III-IV, Partial Response, Complete Response
05/24
12/30
NCT04063527: Phase III Trial of Stage I Ovarian Cancer After Surgery

Recruiting
3
360
Japan, RoW
adjuvant chemotherapy, paclitaxel and carboplatin
Japanese Gynecologic Oncology Group, Korean Gynecologic Oncology Group
Epithelial Ovarian Cancer
10/29
02/30
Contact, See Central
DESTINY-Breast05, NCT04622319 / 2020-003982-20: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy

Jan 2024 - Dec 2024: Data from DESTINY-Breast05 trial for HER2+ post neo-adjuvant breast cancer
Jan 2024 - Dec 2024: Acceptance of of regulatory submission for HER2+ post neo-adjuvant breast cancer (DESTINY-Breast05 trial)
Active, not recruiting
3
1600
Europe, Canada, Japan, US, RoW
DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1)
Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI)
HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer
12/25
12/30
NCT05547087: A Dose Finding Study of VN-0200

Completed
2
342
Japan
VN-0200
Daiichi Sankyo
Respiratory Syncytial Virus Infections
04/23
02/24
HERTHENA-PanTumor01, NCT06172478: A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting
2
400
Europe, Japan, US, RoW
HER3-DXd, Patritumab Deruxtecan, U3-1402
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
06/25
04/26
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Active, not recruiting
2
21
Japan
Pexidartinib, TURALIO™, PLX3397
Daiichi Sankyo Co., Ltd.
Tenosynovial Giant Cell Tumor
03/23
05/26
IDeate-Pantumor 01, NCT04145622: Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Hourglass Sep 2024 - Sep 2024 : Updated data for adv solid tumors
Recruiting
1/2
250
Japan, US
Ifinatamab deruxtecan (I-DXd)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced Solid Tumor, Malignant Solid Tumor
12/25
03/27
KEYNOTE-D35, NCT05438420: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors

Recruiting
1/2
120
US, RoW
Q702, Pembrolizumab, KEYTRUDA®
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer
10/25
06/26
KEYNOTE-E45, NCT05394103: Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors

Recruiting
1/2
130
US, RoW
Q901, KEYTRUDA® (pembrolizumab)
Qurient Co., Ltd., Merck Sharp & Dohme LLC
Advanced Cancer, Metastatic Cancer
12/25
08/26
DS3939-077, NCT05875168: First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors

Recruiting
1/2
430
Europe, Japan, US
DS-3939a
Daiichi Sankyo
Advanced Solid Tumor, Metastatic Solid Tumor
03/26
07/27
U31402-A-U102, NCT03260491: U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer

Checkmark Data from trial for NSCLC
Jan 2021 - Jan 2021: Data from trial for NSCLC
Checkmark Data from trial for EGFRm NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from trial for EGFRm NSCLC at ESMO 2020
Recruiting
1
309
Europe, Japan, US, RoW
HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP)
Daiichi Sankyo, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
03/26
12/26
NCT04648254: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor

Active, not recruiting
1
78
US
Q702
Qurient Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Cancer
12/24
02/25
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer

Jan 2024 - Dec 2024: Data from TROPION-Lung02 trial for advanced or metastatic NSCLC
Checkmark Interim analysis data from TROPION-Lung02 trial for NSCLC
Aug 2022 - Aug 2022: Interim analysis data from TROPION-Lung02 trial for NSCLC
Active, not recruiting
1
145
Europe, Japan, US, RoW
Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin
Daiichi Sankyo, Merck Sharp & Dohme LLC
Advanced or Metastatic NSCLC
06/25
06/25
NCT04419532: A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors

Recruiting
1
40
Canada, Japan, US
DS-1055a
Daiichi Sankyo Co., Ltd.
Solid Tumor, Advanced Cancer, Metastatic Solid Tumor
06/25
06/25
U31402-A-U103, NCT04676477: HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer

Active, not recruiting
1
280
Japan, US, RoW
HER3-DXd, U3-1402, Patritumab deruxtecan, Osimertinib
Daiichi Sankyo, AstraZeneca, Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer (NSCLC)
06/25
02/26
DS1471-079, NCT06074705: A Study of DS-1471a In Subjects With Advanced Solid Tumors

Recruiting
1
80
Japan
DS-1471a
Daiichi Sankyo Co., Ltd.
Advanced Solid Tumor
06/27
06/27
NCT05769764: A Study of Prevalence of HER3 Expression in Non-Small Cell Lung Cancer

Completed
N/A
225
US
Archival tissue specimen and immunohistochemistry staining
Daiichi Sankyo, Inc.
Non-small Cell Lung Cancer
04/23
04/23
Mishima, Kazuhiko
EF-41, NCT06556563: /KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Recruiting
3
741
Japan, US
Optune® device, TTFields, Temozolomide, Pembrolizumab, Placebo
NovoCure GmbH, Merck Sharp & Dohme LLC
Glioblastoma
04/29
04/29
TRIDENT, NCT04471844: Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM

Active, not recruiting
N/A
982
Europe, Canada, Japan, US, RoW
Optune®
NovoCure Ltd.
Glioblastoma Multiforme
01/26
01/26
Hasegawa, Kosei
innovaTV 301, NCT04697628 / 2019-001655-39: Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer

Active, not recruiting
3
502
Europe, Canada, Japan, US, RoW
tisotumab vedotin, TIVDAK, topotecan, vinorelbine, gemcitabine, irinotecan, pemetrexed
Seagen Inc., Genmab
Cervical Cancer
07/23
08/25
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
GOTIC-025, NCT04641728: Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

Active, not recruiting
2
28
Japan
Pembrolizumab, KEYTRUDA, Olaparib, LYNPARZA
Saitama Medical University International Medical Center, Tokyo University, National Cancer Center, Japan, Cancer Institute Hospital, Japan, Aichi Cancer Center
Cervical Cancer
12/22
12/23
NIRVANA-1, NCT05183984 / 2021-004278-76: Niraparib with BeVAcizumab After Complete CytoreductioN in Patients with OvArian Cancer

Recruiting
2
390
Europe, Japan, RoW
Chemotherapy, Bevacizumab-Awwb, Niraparib
ARCAGY/ GINECO GROUP, GSK
Ovarian Cancer
02/27
02/30
RUBY-J, NCT06317311: A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

Recruiting
2
36
Japan
Dostarlimab, Carboplatin, Paclitaxel
GlaxoSmithKline
Carcinoma
07/26
08/27
SaINT-ov02, NCT05158062: Pembrolizumab and Bevacizumab With Chemotherapy Followed by Pembrolizumab, Bevacizumab and Olaparib in Recurrent Ovarian Cancer

Recruiting
2
35
Japan
pembrolizumab, KEYTRUDA, olaparib, LYNPARZA, bevacizumab, AVASTIN, carboplatin, paclitaxel, docetaxel
Kosei Hasegawa, MD, PhD
Carcinoma, Ovarian Epithelial
11/24
11/24
NCT06555744: A Study of ZW191 in Participants With Solid Tumors

Recruiting
1
145
Japan, US, RoW
ZW191
Zymeworks BC Inc.
Advanced Solid Tumors
12/26
01/27
Loreen, Mark
EF-41, NCT06556563: /KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma

Recruiting
3
741
Japan, US
Optune® device, TTFields, Temozolomide, Pembrolizumab, Placebo
NovoCure GmbH, Merck Sharp & Dohme LLC
Glioblastoma
04/29
04/29
NCT03382977: Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Recruiting
1/2
98
US
VBI-1901, Carmustine, BiCNU, Lomustine, Gleostine
VBI Vaccines Inc.
Glioblastoma Multiforme
07/25
08/25
NCT04520776: A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Single Level Cervical Disc Disease

Active, not recruiting
N/A
284
US
BAGUERA®C Cervical Disc Prosthesis, Mobi-C® Cervical Disc
Spineart USA
Cervical Disc Disease
02/26
02/26
NCT04564885: A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Cervical Disc Disease at 2 Contiguous Levels

Active, not recruiting
N/A
300
US
BAGUERA®C Cervical Disc Prosthesis, Mobi-C Cervical Disc
Spineart USA
Cervical Disc Disease
04/25
04/30
TLIF, NCT04073563: Transforaminal Lumbar Interbody Fusion

Recruiting
N/A
1017
US, RoW
Infuse™ Bone Graft (Infuse™), Intervertebral body fusion device and Medtronic posterior Fixation Systems
Medtronic Spinal and Biologics
Degenerative Disease of the Lumbosacral Spine
04/26
04/28

Download Options